

Financial news for CFRXW dated on 2016-11-17: ContraFect Wins \$2.1M Grant

Financial news for CFRXW dated on 2016-11-14: ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria

Financial news for CFRXW dated on 2015-12-15: ContraFect Corporation Concludes Phase 1 Study of CF-301, DSMB Observed No Clinical Adverse Safety Signals In Study

Financial news for CFRXW dated on 2015-08-17: FDA Gives Fast Track Designation to ContraFect's CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA